In 2018, the FDA modified this indication to be used either for patients ineligible for cisplatin with PDL-1 stained tumor infiltrating cells >5%, or for patients ineligible for any platinum-based therapy, regardless of PD-L1 expression (49). The gene discussed is CD274; the disease is neoplasm.